Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia VeraBusiness Wire • 08/28/26
ORZEYFUL (oveporexton) Approved in Japan as the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1Business Wire • 08/24/26
Wall Street Analysts Think Takeda Pharmaceutical Co. (TAK) Could Surge 26.41%: Read This Before Placing a BetZacks Investment Research • 08/18/26
Should Value Investors Buy Takeda Pharmaceutical Co. (TAK) Stock?Zacks Investment Research • 08/17/26
Takeda's Pipeline Looks Encouraging, But Generic Erosion Is A Near-Term ConcernSeeking Alpha • 08/07/26
U.S. FDA Approves Takeda's ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1Business Wire • 08/05/26
Takeda Announces FY2026 First Quarter Results, Near-Term Launch Preparations and Pipeline Progress on TrackBusiness Wire • 07/30/26
Takeda's Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis StudiesBusiness Wire • 07/16/26
Takeda and the Indonesian Government Announce Landmark Collaboration to Strengthen Healthcare Resilience and Expand Access to Lifesaving Plasma-Derived Medicinal ProductsBusiness Wire • 07/12/26
Insilico Medicine Announces Collaboration with Takeda to Advance Strategic AI Drug DiscoveryPRNewsWire • 07/02/26
Takeda Announces New Assignments of Directors and Appointment of Julie Kim as Representative Director, President and CEOBusiness Wire • 06/24/26
New Pivotal Study Data Show Takeda's Oveporexton Improved Daily Function, Cognition and Nighttime Sleep for People with Narcolepsy Type 1Business Wire • 06/15/26
Takeda Designed A Psoriasis Pill Using AI. It Just Walloped Bristol's Sotyktu In A Head-To-Head Test.Investors Business Daily • 06/11/26
Takeda's AI-crafted psoriasis pill tops Bristol Myers' Sotyktu in head-to-head trialReuters • 06/11/26
Takeda's Zasocitinib Significantly Outperforms Deucravacitinib in Head-to-Head Phase 3 Psoriasis Study, Promising to Redefine Oral Treatment ExpectationsBusiness Wire • 06/11/26